VCYT•businesswire•
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Summary
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 11, 2026 by businesswire